Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes: the Hypo-RESOLVE hypoglycaemic clamp study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes : the Hypo-RESOLVE hypoglycaemic clamp study. / Fabricius, Therese W.; Verhulst, Clementine E. M.; Kristensen, Peter L.; Holst, Jens J.; Tack, Cees J.; McCrimmon, Rory J.; Heller, Simon R.; Evans, Mark L.; de Galan, Bastiaan E.; Pedersen-Bjergaard, Ulrik; Hypo-RESOLVE Consortium.

In: Acta Diabetologica, Vol. 61, No. 5, 2024, p. 623-633.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Fabricius, TW, Verhulst, CEM, Kristensen, PL, Holst, JJ, Tack, CJ, McCrimmon, RJ, Heller, SR, Evans, ML, de Galan, BE, Pedersen-Bjergaard, U & Hypo-RESOLVE Consortium 2024, 'Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes: the Hypo-RESOLVE hypoglycaemic clamp study', Acta Diabetologica, vol. 61, no. 5, pp. 623-633. https://doi.org/10.1007/s00592-024-02239-8

APA

Fabricius, T. W., Verhulst, C. E. M., Kristensen, P. L., Holst, J. J., Tack, C. J., McCrimmon, R. J., Heller, S. R., Evans, M. L., de Galan, B. E., Pedersen-Bjergaard, U., & Hypo-RESOLVE Consortium (2024). Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes: the Hypo-RESOLVE hypoglycaemic clamp study. Acta Diabetologica, 61(5), 623-633. https://doi.org/10.1007/s00592-024-02239-8

Vancouver

Fabricius TW, Verhulst CEM, Kristensen PL, Holst JJ, Tack CJ, McCrimmon RJ et al. Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes: the Hypo-RESOLVE hypoglycaemic clamp study. Acta Diabetologica. 2024;61(5):623-633. https://doi.org/10.1007/s00592-024-02239-8

Author

Fabricius, Therese W. ; Verhulst, Clementine E. M. ; Kristensen, Peter L. ; Holst, Jens J. ; Tack, Cees J. ; McCrimmon, Rory J. ; Heller, Simon R. ; Evans, Mark L. ; de Galan, Bastiaan E. ; Pedersen-Bjergaard, Ulrik ; Hypo-RESOLVE Consortium. / Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes : the Hypo-RESOLVE hypoglycaemic clamp study. In: Acta Diabetologica. 2024 ; Vol. 61, No. 5. pp. 623-633.

Bibtex

@article{ccadba0b13e4489fbe0bf19108d147b4,
title = "Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes: the Hypo-RESOLVE hypoglycaemic clamp study",
abstract = "Aim: The sympathetic nervous and hormonal counterregulatory responses to hypoglycaemia differ between people with type 1 and type 2 diabetes and may change along the course of diabetes, but have not been directly compared. We aimed to compare counterregulatory hormone and symptom responses to hypoglycaemia between people with type 1 diabetes, insulin-treated type 2 diabetes and controls without diabetes, using a standardised hyperinsulinaemic-hypoglycaemic clamp. Materials: We included 47 people with type 1 diabetes, 15 with insulin-treated type 2 diabetes, and 32 controls without diabetes. Controls were matched according to age and sex to the people with type 1 diabetes or with type 2 diabetes. All participants underwent a hyperinsulinaemic–euglycaemic-(5.2 ± 0.4 mmol/L)-hypoglycaemic-(2.8 ± 0.13 mmol/L)-clamp. Results: The glucagon response was lower in people with type 1 diabetes (9.4 ± 0.8 pmol/L, 8.0 [7.0–10.0]) compared to type 2 diabetes (23.7 ± 3.7 pmol/L, 18.0 [12.0–28.0], p < 0.001) and controls (30.6 ± 4.7, 25.5 [17.8–35.8] pmol/L, p < 0.001). The adrenaline response was lower in type 1 diabetes (1.7 ± 0.2, 1.6 [1.3–5.2] nmol/L) compared to type 2 diabetes (3.4 ± 0.7, 2.6 [1.3–5.2] nmol/L, p = 0.001) and controls (2.7 ± 0.4, 2.8 [1.4–3.9] nmol/L, p = 0.012). Growth hormone was lower in people with type 2 diabetes than in type 1 diabetes, at baseline (3.4 ± 1.6 vs 7.7 ± 1.3 mU/L, p = 0.042) and during hypoglycaemia (24.7 ± 7.1 vs 62.4 ± 5.8 mU/L, p = 0.001). People with 1 diabetes had lower overall symptom responses than people with type 2 diabetes (45.3 ± 2.7 vs 58.7 ± 6.4, p = 0.018), driven by a lower neuroglycopenic score (27.4 ± 1.8 vs 36.7 ± 4.2, p = 0.012). Conclusion: Acute counterregulatory hormone and symptom responses to experimental hypoglycaemia are lower in people with type 1 diabetes than in those with long-standing insulin-treated type 2 diabetes and controls.",
keywords = "Counterregulatory response, Diabetes, Hyperinsulinaemic–hypoglycaemic clamp, Hypoglycaemia",
author = "Fabricius, {Therese W.} and Verhulst, {Clementine E. M.} and Kristensen, {Peter L.} and Holst, {Jens J.} and Tack, {Cees J.} and McCrimmon, {Rory J.} and Heller, {Simon R.} and Evans, {Mark L.} and {de Galan}, {Bastiaan E.} and Ulrik Pedersen-Bjergaard and {Hypo-RESOLVE Consortium}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",
year = "2024",
doi = "10.1007/s00592-024-02239-8",
language = "English",
volume = "61",
pages = "623--633",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Counterregulatory hormone and symptom responses to hypoglycaemia in people with type 1 diabetes, insulin-treated type 2 diabetes or without diabetes

T2 - the Hypo-RESOLVE hypoglycaemic clamp study

AU - Fabricius, Therese W.

AU - Verhulst, Clementine E. M.

AU - Kristensen, Peter L.

AU - Holst, Jens J.

AU - Tack, Cees J.

AU - McCrimmon, Rory J.

AU - Heller, Simon R.

AU - Evans, Mark L.

AU - de Galan, Bastiaan E.

AU - Pedersen-Bjergaard, Ulrik

AU - Hypo-RESOLVE Consortium

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024

Y1 - 2024

N2 - Aim: The sympathetic nervous and hormonal counterregulatory responses to hypoglycaemia differ between people with type 1 and type 2 diabetes and may change along the course of diabetes, but have not been directly compared. We aimed to compare counterregulatory hormone and symptom responses to hypoglycaemia between people with type 1 diabetes, insulin-treated type 2 diabetes and controls without diabetes, using a standardised hyperinsulinaemic-hypoglycaemic clamp. Materials: We included 47 people with type 1 diabetes, 15 with insulin-treated type 2 diabetes, and 32 controls without diabetes. Controls were matched according to age and sex to the people with type 1 diabetes or with type 2 diabetes. All participants underwent a hyperinsulinaemic–euglycaemic-(5.2 ± 0.4 mmol/L)-hypoglycaemic-(2.8 ± 0.13 mmol/L)-clamp. Results: The glucagon response was lower in people with type 1 diabetes (9.4 ± 0.8 pmol/L, 8.0 [7.0–10.0]) compared to type 2 diabetes (23.7 ± 3.7 pmol/L, 18.0 [12.0–28.0], p < 0.001) and controls (30.6 ± 4.7, 25.5 [17.8–35.8] pmol/L, p < 0.001). The adrenaline response was lower in type 1 diabetes (1.7 ± 0.2, 1.6 [1.3–5.2] nmol/L) compared to type 2 diabetes (3.4 ± 0.7, 2.6 [1.3–5.2] nmol/L, p = 0.001) and controls (2.7 ± 0.4, 2.8 [1.4–3.9] nmol/L, p = 0.012). Growth hormone was lower in people with type 2 diabetes than in type 1 diabetes, at baseline (3.4 ± 1.6 vs 7.7 ± 1.3 mU/L, p = 0.042) and during hypoglycaemia (24.7 ± 7.1 vs 62.4 ± 5.8 mU/L, p = 0.001). People with 1 diabetes had lower overall symptom responses than people with type 2 diabetes (45.3 ± 2.7 vs 58.7 ± 6.4, p = 0.018), driven by a lower neuroglycopenic score (27.4 ± 1.8 vs 36.7 ± 4.2, p = 0.012). Conclusion: Acute counterregulatory hormone and symptom responses to experimental hypoglycaemia are lower in people with type 1 diabetes than in those with long-standing insulin-treated type 2 diabetes and controls.

AB - Aim: The sympathetic nervous and hormonal counterregulatory responses to hypoglycaemia differ between people with type 1 and type 2 diabetes and may change along the course of diabetes, but have not been directly compared. We aimed to compare counterregulatory hormone and symptom responses to hypoglycaemia between people with type 1 diabetes, insulin-treated type 2 diabetes and controls without diabetes, using a standardised hyperinsulinaemic-hypoglycaemic clamp. Materials: We included 47 people with type 1 diabetes, 15 with insulin-treated type 2 diabetes, and 32 controls without diabetes. Controls were matched according to age and sex to the people with type 1 diabetes or with type 2 diabetes. All participants underwent a hyperinsulinaemic–euglycaemic-(5.2 ± 0.4 mmol/L)-hypoglycaemic-(2.8 ± 0.13 mmol/L)-clamp. Results: The glucagon response was lower in people with type 1 diabetes (9.4 ± 0.8 pmol/L, 8.0 [7.0–10.0]) compared to type 2 diabetes (23.7 ± 3.7 pmol/L, 18.0 [12.0–28.0], p < 0.001) and controls (30.6 ± 4.7, 25.5 [17.8–35.8] pmol/L, p < 0.001). The adrenaline response was lower in type 1 diabetes (1.7 ± 0.2, 1.6 [1.3–5.2] nmol/L) compared to type 2 diabetes (3.4 ± 0.7, 2.6 [1.3–5.2] nmol/L, p = 0.001) and controls (2.7 ± 0.4, 2.8 [1.4–3.9] nmol/L, p = 0.012). Growth hormone was lower in people with type 2 diabetes than in type 1 diabetes, at baseline (3.4 ± 1.6 vs 7.7 ± 1.3 mU/L, p = 0.042) and during hypoglycaemia (24.7 ± 7.1 vs 62.4 ± 5.8 mU/L, p = 0.001). People with 1 diabetes had lower overall symptom responses than people with type 2 diabetes (45.3 ± 2.7 vs 58.7 ± 6.4, p = 0.018), driven by a lower neuroglycopenic score (27.4 ± 1.8 vs 36.7 ± 4.2, p = 0.012). Conclusion: Acute counterregulatory hormone and symptom responses to experimental hypoglycaemia are lower in people with type 1 diabetes than in those with long-standing insulin-treated type 2 diabetes and controls.

KW - Counterregulatory response

KW - Diabetes

KW - Hyperinsulinaemic–hypoglycaemic clamp

KW - Hypoglycaemia

U2 - 10.1007/s00592-024-02239-8

DO - 10.1007/s00592-024-02239-8

M3 - Journal article

C2 - 38376580

AN - SCOPUS:85185253417

VL - 61

SP - 623

EP - 633

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 5

ER -

ID: 383782345